[8-K] Invivyd, Inc. Reports Material Event

Rhea-AI Filing Summary

Invivyd, Inc. reported that it has issued a press release announcing the selection of RSV antibody candidate VBY329, which it describes as a potential best-in-class therapy. The company stated in the release title that it is targeting investigational new drug (IND) readiness for this candidate in the second half of 2026, signaling a planned next step toward clinical development. This update was furnished as an informational 8-K under Other Events, along with the full press release as an exhibit.

Insights

Biotech pipeline and regulatory analyst

Invivyd highlights a new RSV antibody candidate with an indicated IND timeline.

Invivyd has disclosed the selection of RSV antibody candidate VBY329, described as a potential best-in-class option, and referenced a plan to achieve IND readiness in the second half of 2026. This marks a defined advancement point in its pipeline, even though no efficacy, safety, or detailed development data are included here.

The reference to IND readiness suggests an intention to complete the preclinical and regulatory preparatory work needed to seek permission to begin human studies. Actual progress will depend on future results and regulatory interactions that are not described in this excerpt. Subsequent company communications and filings would need to provide the supporting data, study design details, and any changes to timing.

false000183203800018320382025-11-242025-11-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 24, 2025

Invivyd, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40703		85-1403134
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

209 Church Street New Haven, CT		06510
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 819-0080

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		IVVD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 24, 2025, Invivyd, Inc. issued a press release entitled “Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness.” A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated November 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INVIVYD, INC.
Date: November 24, 2025		By:	/s/ Jill Andersen
			Jill Andersen
			Chief Legal Officer and Corporate Secretary

FAQ

What did Invivyd (IVVD) announce in this 8-K filing?

Invivyd reported that it issued a press release titled “Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness.” The 8-K primarily serves to furnish that press release as an exhibit.

What is VBY329 in Invivyds recent 8-K for IVVD?

VBY329 is the RSV antibody candidate that Invivyd describes in the press release as a potential best-in-class therapy. The filing notes that this candidate has been selected and highlighted in the companys press release.

What development timing did Invivyd indicate for VBY329 in the 8-K?

The press release title states that Invivyd is targeting IND readiness for VBY329 in the second half of 2026, indicating when the company aims to be prepared to seek permission to begin clinical testing.

Which SEC item does this Invivyd (IVVD) 8-K relate to?

The event is presented under Item 8.01, Other Events, which is used to report significant events or corporate updates that the company chooses to disclose even though they are not specifically required under other 8-K items.

What exhibits are included with Invivyds 8-K about VBY329?

The filing lists Exhibit 99.1 as the press release dated November 24, 2025, and also references Exhibit 104 as the cover page interactive data file embedded in the Inline XBRL document.

Does the Invivyd (IVVD) 8-K provide clinical data for VBY329?

The excerpt only states that Invivyd issued a press release announcing the selection of potential best-in-class RSV antibody candidate VBY329 and targeting IND readiness in the second half of 2026; it does not include clinical or preclinical data.